Date published: 
2 September 2022
Type: 
News
Intended audience: 
General public
ATAGI update following weekly COVID-19 meeting – 31 August 2022

Latest recommendation updates

ATAGI have not published any recommendations since 25 August 2022. Recent meeting deliberations can be found on the ATAGI page.

Recent ATAGI considerations

On Wednesday 31 August 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 29 August, over 63 million doses of COVID-19 vaccines have been administered in Australia.

Consideration of variant vaccines

On 29 August 2022 the Therapeutic Goods Administration (TGA) granted provisional approval for the Moderna bivalent COVID-19 vaccine, Spikevax Bivalent Zero/Omicron.

Following this announcement, ATAGI have continued to discuss the role of this new bivalent COVID-19 vaccine in Australia’s COVID-19 vaccination program and are currently finalising advice to the Minister for Health and Aged Care on the use of this vaccine.

ATAGI continue to emphasise the importance of receiving the COVID-19 vaccinations recommended for your age or individual health needs.

Ongoing review of COVID-19 vaccine safety

The TGA Fortnightly Report provides a detailed breakdown of adverse events following immunisation, including Australian rates of myocarditis and pericarditis.

Resources and recent statements

More information can be found in the following resources:

More information can be found on the Department of Health and Aged Care website, with resources for both providers and patients.